secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001628280-24-046920
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen presents positive OCU400 clinical data: 84% less atrophy area in treated vs untreated
--------------------------------------------------------------------------------

- OCU400 (AAV encoding NR2E3) shows restoration of phototransduction genes and improved retinal structure in multiple RP/LCA models.
- Mean change in total atrophy area from baseline: +0.12 mm² treated vs +0.73 mm² untreated (84% improvement).
- LL VA change from baseline: treated patients improved while untreated declined over 12 months.
- Preclinical ERG and histology data show slowed degeneration across five animal models (Rho-/-, RhoP23H+/-, Rd7, Rd1, Rd16).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000162828024046920/0001628280-24-046920-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000162828024046920/ocgn-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-046920

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer